MKNK2 and central nervous system cancer: Across GBM subtypes, both MKNK1 and MKNK2 genes are highly expressed in mesenchymal subtype GBM, while only the MKNK1 expression correlates with the mesenchymal glioma stem cells marker CD44 and predicts poor survival in GBM when both genes are upregulated [81,147].